Connect with us

Hi, what are you looking for?

Stock

Amicus stock surges on positive 2024 revenue outlook

Investing.com — Shares of Amicus Therapeutics (NASDAQ:FOLD) jumped 9% as the biotech company provided an optimistic preliminary revenue outlook for 2024, along with expectations to achieve positive GAAP net income in the second half of the year.

The significant movement in Amicus shares reflects investor confidence following the company’s announcement that it anticipates a strong financial performance in the upcoming year.

The premarket trading surge comes after the company’s statement that, based on its current operating plans, it is on track to report positive GAAP net income during the latter half of 2024.

BofA analysts commented on the news: “We remain encouraged by the continued growth of Galafold as the main revenue driver but see significant opportunity for growth from P&O as we await future regulatory updates.”

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

This post appeared first on investing.com

You May Also Like

Editor's Pick

Adani Group shares experienced a rebound on Monday, recovering from last week’s steep losses sparked by U.S. criminal charges against Chairman Gautam Adani and...

Economy

By Leika Kihara TOKYO (Reuters) -Some Bank of Japan policymakers saw conditions falling into place for an imminent rate hike with one predicting a...

Latest News

The Department of Defense (DoD) announced two weapons packages for Ukraine on Monday, totaling $2.47 billion. The first of the two, the Presidential Drawdown...

Latest News

It was former President Obama who famously quipped that ‘elections have consequences,’ and one of the consequences of the 2024 election is that President-elect...



Disclaimer: Techreportdiversity.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


Copyright © 2024 Techreportdiversity.com